Skip to main content
    A

    Akari Therapeutics PLC (AKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.19
    -0.61 (-8.97%)

    Market Cap: $15.54M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Akari Therapeutics PLC (AKTX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Akari Therapeutics (AKTX) to earn -$9.05 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$8.65.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$9.05
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$8.65
    EPS consensus
    Fiscal year ending Dec 31, 2028
    -$6.27
    EPS consensus
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$9.05-$9.05 to -$9.051
    Dec 31, 2027-$8.65-$8.65 to -$8.651
    Dec 31, 2028-$6.27-$6.27 to -$6.272

    Quarterly Estimates

    The EPS consensus falls from -$0.94 for the quarter ending Dec 31, 2026 to -$2.09 for the quarter ending Mar 31, 2027.

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.94N/A4
    Mar 31, 2027-$2.09-$2.09 to -$2.091

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202700

    Frequently Asked Questions About AKTX

    What is the AKTX stock forecast?

    Consensus analyst estimates put Akari Therapeutics's EPS at -$9.05 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from AKTX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$9.05, with estimates from -$9.05 to -$9.05 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.65, with estimates from -$8.65 to -$8.65 from 1 analyst.

    How many analysts cover AKTX?

    1 analyst estimates EPS for Akari Therapeutics for the fiscal year ending Dec 31, 2026.